Clinical Scorecard: Utilization of Decellularized Dermis Allografts in Managing Venous Leg Ulcers: Insights from the DAVE Randomized Controlled Trial

At a Glance

Key Highlights

• DAVE trial was a randomized controlled trial comparing DCD allograft plus standard care versus standard care alone for VLUs.
• No significant improvement in healing rates at 12 weeks was observed with DCD allografts (5.7% vs 15.2% control).
• Trial was terminated early due to lower-than-expected healing rates and small sample size limiting definitive conclusions.

Guideline-Based Recommendations

Diagnosis

• Confirm venous leg ulcer diagnosis with duplex ultrasound demonstrating venous incompetence.
• Assess ankle-brachial pressure index to exclude significant arterial disease (≥0.8 required).
• Evaluate ulcer size and duration (≥2 cm² and ≥3 months) for eligibility.

Management

• Standard care includes wound cleaning, debridement, and multilayer elastic compression therapy.
• Adjunctive treatments such as skin grafting (autografts, allografts, tissue-engineered skin) may be considered to accelerate healing.
• DCD allografts can be applied under local anesthesia using staples, sutures, or tissue glue without hospital admission.

Monitoring & Follow-up

• Monitor ulcer healing progress including ulcer area reduction and time to healing.
• Assess for adverse events related to graft application.
• Evaluate recurrence rates and patient quality of life over follow-up.

Risks

• Potential for serious adverse events related to DCD application as observed in trial.
• No clear evidence of harm or benefit due to small sample size and early trial termination.
• Compression therapy contraindications should be considered based on arterial status.

Patient & Prescribing Data

Adults with chronic venous leg ulcers meeting inclusion criteria in UK clinical settings.

DCD allografts did not demonstrate improved healing rates compared to standard care alone in this trial; safety profile requires further evaluation due to observed serious adverse events.

Clinical Best Practices

• Use duplex ultrasound and ankle-brachial pressure index to confirm venous etiology and exclude arterial disease before treatment.
• Apply standard compression therapy as the cornerstone of VLU management.
• Consider adjunctive skin grafting therapies cautiously, recognizing current evidence limitations.
• Monitor patients closely for healing progress and adverse events when using novel graft materials.
• Inform patients about the uncertain benefit and potential risks of DCD allografts based on current evidence.

References

• DAVE Trial Registration